• The real winners of the Firmus fiasco

    A group of young people lined up on a wall are happy looking at their laptops and devices as they invest in the latest trendy stock.

    This time last week, Firmus Technologies was gearing up to launch the biggest ASX initial public offering (IPO) in 30 years.

    On the back of the artificial intelligence (AI) boom and Space X‘s Nasdaq listing earlier this year, it was being sold as the biggest ASX listing in a generation. With little opportunity to invest in the local market, ASX tech enthusiasts faced a rare opportunity.

    Firmus’ broker syndicate had told prospective investors that early indications of interest were well above the offer size. They said that more than half the raise would likely go to existing investors. This implied that there would be very little left for retail investors to participate. In other words, most would miss out.

    By Thursday morning, the narrative began to swiftly change.

    First came news of repricing. As institutional enthusiasm began to dwindle, it was revealed that the offer price had been reduced. Initially from $11 to $9, then $8.25. According to the Australian Financial Review, a figure as low as $6 was considered. This represented a nearly 50% decline from the starting offer price in less than 24 hours.

    Not long after, Bloomberg News broke the news that the IPO had been cancelled. Several other news organisations quickly confirmed it.

    The blame game then began. What would happen to Firmus now? How could things go so wrong so quickly? 

    Many echoed the sentiment of long-time Firmus backer David Paradice, Managing Director of Paradice Investment Management, who was puzzled as to how demand could evaporate so quickly.

    According to the Australian Financial Review, he said:

    We were told there were massive bids coming out of America, which clearly never eventuated. There was a big difference between what the underwriters were saying and the outcome.

    At least two major groups of stakeholders will come off most bruised. Of course, the founders and existing investors who stood to book an enormous profit, should the IPO have gone ahead at $11. However, the broker syndicate will also have a lot to answer for. At the very least, there will be reputational damage and lost fees.

    While plenty of stories will be written about the losers of the abandoned Firmus IPO, we should take a moment to mention the group of investors who have most certainly come out on top.

    A victory for retail investors

    When investing alongside insiders and institutional investors, retail investors often feel like they are at a disadvantage. Not just because they lack professional expertise, but also because they feel they have an information handicap. 

    In the case of IPOs, this is often magnified. The Firmus listing was no exception. 

    In fact, Ten Cap portfolio manager Jun Bei Liu described the Firmus IPO as “probably one of the most polarising IPOs [she has] ever seen”, and noted that “the lack of detail they disclose [was] unprecedented.”

    Companies like Firmus, with little operating history, are difficult to value. Without adequate disclosure in other areas, it brings a whole other layer of challenge.

    This makes it even harder for retail investors to decide whether to participate. 

    According to the Australian Financial Review, Firmus’ targeted valuation of $43.7 billion on FY26 and its operating revenue of around $70 million implied a price-to-revenue of around 860 times!

    For context, SpaceX listed at a price-to-revenue multiple of 94 times, which was widely considered as lofty.

    By pulling the IPO, retail investors were spared from having to value Firmus and decide whether it was worth the hype. 

    Saved from the winner’s curse

    Behind this phenomenon is a theory known as the ‘winner’s curse’.

    The winner’s curse suggests IPOs favour the well-connected with deep pockets. 

    In an underpriced IPO, institutional investors act on their advantage to take up a large allocation, pricing retail investors out. 

    When an IPO is overvalued, the opposite occurs. Institutional investors may bail after learning that it is overvalued. Retail investors then end up getting their full allocations. When the company lists, the valuation drops, and retail investors are left to watch their investment crater.

    However, in Firmus’ case, this played out before it listed. Reports of an excessive valuation and a lack of interest were made public, leading to its cancellation. Retail investors were spared.

    Retail investor JOMO (joy of missing out!)

    Now that the IPO has been called off and the blame game has started, many will argue that Firmus’ IPO was always destined to fail. They will say they never would have invested. 

    However, hindsight is a powerful thing, and the Firmus hype was real. The float was backed by some very big players, including Nvidia, Blackstone, and some of the world’s biggest investment banks.

    It’s likely that many retail investors would have been caught up in the euphoria and invested in the ‘biggest IPO in a generation’ at the earliest opportunity.

    There are certainly lessons to be learnt.

    However, for now, retail investors should take the win.

    Should the ASX IPO have proceeded at the original price of $11, Firmus’ banking syndicate stood to earn fees of around $215 million.

    Instead, Firmus was forced to abandon the IPO and will have a lot to answer for. 

    Retail investors walk away unscathed, free to allocate their capital to their next promising investment. 

    The post The real winners of the Firmus fiasco appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Blackstone and Nvidia. The Motley Fool Australia has recommended Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Buy, hold, sell: Mesoblast, Transurban, NextDC shares

    A broker caluculates a hold rating for an asx share price

    S&P/ASX 200 Index (ASX: XJO) shares are up 0.4% to 8,749.7 points on Monday.

    Among the 11 market sectors, information technology is in the lead today, up 2.3%.

    The consumer staples sector is the laggard, down 1.4%.

    Here are some new recommendations from the experts.

    Mesoblast Ltd (ASX: MSB)

    The Mesoblast share price is $2.02, up 0.8% today and down 29% over 12 months. 

    Bell Potter has a buy rating with a 12-month price target of $4.45 on this ASX 200 healthcare share. 

    Analyst John Hester said: 

    The short term outlook for Mesoblast’s revenue growth remains highly attractive.

    Pivotal events for valuation are approaching, including the interim readout on the adult GvHD study (1QCY27) and the headline data from the chronic lower back pain trial (CLBP) due mid CY27.

    Both are substantially larger markets than paediatric GvHD, nevertheless the market remains cautious.

    Australian biotech has had a difficult 12 months with several randomised clinical trials failing to meet clinical endpoints and we expect this has undermined investor confidence in the sector and is a contributing factor to the recent MSB share price.

    While there is inherent risk in clinical trials, there is little to no read through from recent performance of others to MSB.

    Transurban Group (ASX: TCL)

    The Transurban share price is $13.15, down 0.8% today and down 8% over 12 months. 

    Blake Halligan from Gray Perry Wealth Advisers has a hold rating on this ASX 200 industrials share. 

    Halligan said (courtesy The Bull): 

    Transurban owns and operates toll roads across Australia and North America, generating cash flows from essential transport infrastructure.

    The company recently agreed to acquire additional interests in Sydney toll roads, which should support longer term earnings and cash flow growth.

    No equity funding is required for the $4.5 billion deal.

    However, in our view, the benefits are likely to be offset in the near term by increased funding requirements, elevated leverage and ongoing sensitivity to interest rates.

    Dependable earnings is challenged by limited immediate upside.

    NextDC Ltd (ASX: NXT)

    The NextDC share price is $10.38, up 0.1% today and down 34% over 12 months. 

    Tom Fairchild from Lazarus Capital Partners has a sell rating on this ASX 200 tech share. 

    Fairchild said: 

    NXT is riding the AI data centre boom. The company generated total revenue of $496.5 million in full year 2026, up 16 per cent on the prior corresponding period.

    To fund capital expenditure of $3.397 billion in full year 2026, NXT raised $9.75 billion, much of it in senior debt, subordinated notes and hybrid securities.

    The company’s $82.1 million statutory profit relied on a revaluation gain of $128.8 million.

    In our view, rising interest costs could squeeze returns before new capacity starts paying its way.

    The shares have fallen from $16.37 on June 4 to trade at $10.23 on October 8.

    The post Buy, hold, sell: Mesoblast, Transurban, NextDC shares appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Mesoblast right now?

    Before you buy Mesoblast shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Transurban Group. The Motley Fool Australia has positions in and has recommended Transurban Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Buy, hold, sell: Resmed, Megaport, ANZ shares

    Male investor holds a magnifying glass to his eye.

    S&P/ASX 200 Index (ASX: XJO) shares rose 0.4% last week and are down almost 2% over 12 months.

    Let’s start the new week with some fresh ratings from the experts (courtesy The Bull). 

    ResMed Inc (ASX: RMD)

    The Resmed share price is $32.85, up 0.8% today and down 21% over 12 months. 

    Blake Halligan from Gray Perry Wealth Advisers has a buy rating on this ASX 200 healthcare share. 

    Halligan said: 

    ResMed is a global leader in treating sleep apnoea and in respiratory care devices, with a growing digital health ecosystem that supports long term recurring revenue.

    Revenue increased 8 per cent in constant currency in full year 2026 when compared to the prior corresponding period.

    Earnings per share were up 17 per cent.

    ResMed continues to benefit from an under-penetrated market, with less than 20 per cent of US sleep apnoea sufferers diagnosed or treated amid growing demand for home-based health care solutions.

    We believe concerns around GLP-1 weight loss drugs impacting ResMed are overstated.

    Expanding patient support provides an attractive long term growth outlook.

    Megaport Ltd (ASX: MP1)

    The Megaport share price is $19.67, up 4.7% today and up 39% over 12 months. 

    Philippe Bui from Medallion Financial Group has a hold rating on this ASX 200 tech share. 

    Bui said: 

    Megaport’s expansion into AI infrastructure is generating momentum, with about $979 million in new contracts supporting upgraded full year 2027 revenue guidance of between $720 million and $810 million.

    Pre-payments from these contracts totalling about $322.6 million help fund deployment and strengthen the growth case.

    Forecast capital expenditure of between $1.78 billion to $1.88 billion highlights the scale of its transformation.

    We recommend holding while monitoring delivery, customer concentration and the returns generated from this substantial investment.

    ANZ Group Holdings Ltd (ASX: ANZ)

    The ANZ share price is $37.23, up 0.1% today and up 3% over 12 months. 

    Tom Fairchild from Lazarus Capital Partners has a sell rating on this ASX 200 bank share. 

    Fairchild said: 

    The bank faces headwinds as Australian house prices fall. After acquiring Suncorp Bank, ANZ is the country’s third largest home lender.

    The bank noted a 12 per cent fall in home loan application values since the May budget and the end of July following the Federal Government’s proposed changes to negative gearing and capital gains tax.

    Capital city house prices may fall more than 10 per cent from their peak, raising negative equity risks among recent low deposit buyers, which may pressure lending growth and credit quality.

    Investors may want to consider cashing in some gains given the share price rise since June.

    The post Buy, hold, sell: Resmed, Megaport, ANZ shares appeared first on The Motley Fool Australia.

    Should you invest $1,000 in ResMed right now?

    Before you buy ResMed shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Megaport and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Sorry, but nothing was found. Please try a search with different keywords.